跳至主要内容
临床试验/NCT01460238
NCT01460238已完成不适用

Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia

Dartmouth-Hitchcock Medical Center1 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2011年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
29
试验地点
1
主要终点
LPL Protein Expression

研究概览

简要总结

The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.

详细描述

The investigators plan to use a novel antibody developed at Dartmouth-Hitchcock Medical Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will be analyzed by flow cytometry to detect the expression of LPL and to investigate if LPL expression correlates with a more aggressive type of CLL. The investigators propose that LPL protein expression on CLL cells is prognostic and that LPL and other proteins involved in fatty acid metabolism are critical for CLL cells to survive.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
  • Patients undergoing routine blood draws as part of their ongoing follow up for CLL
  • 18 years or older
  • Ability to provide consent in English
  • Patient must have measurable disease as defined by an absolute lymphocyte count greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL involvement.

排除标准

  • Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL,
  • other hematologic malignancy or other disease process within the past 6 months are excluded.

结局指标

主要结局

LPL Protein Expression

时间窗: 1 year

Determine the degree of LPL protein expression in CLL cells using a novel LPL antibody, correlate with IgHV mutation status, and compare this association with other prognostic markers

次要结局

  • Fatty acid acquisition and synthesis(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Frederick Lansigan

Assistant Professor of Medicine

Dartmouth-Hitchcock Medical Center

研究点 (1)

Loading locations...

相似试验